2 results
Approved WMOCompleted
Primary:• To compare overall survival (OS) in patientsrandomized to NGR-hTNF plus BIC versuspatients randomized to placebo plus BICSecondary:• To compare progression-free survival (PFS)• To compare disease control rate (DCR, defined asthe percentage…
Approved WMOPending
Primary:To assess the safety and tolerability of DS-1211b compared with placebo in subjects with PXE.To assess the dose response by assessing the treatment changes in PD endpoints.